Skip to Content

ACCUSOL 35 POTASSIUM 2MMOL/L SOLUTION FOR HAEMOFILTRATION

Active substance(s): CALCIUM CHLORIDE / GLUCOSE ANHYDROUS / GLUCOSE MONOHYDRATE / MAGNESIUM CHLORIDE / MAGNESIUM CHLORIDE HEXAHYDRATE / POTASSIUM CHLORIDE / SODIUM BICARBONATE / SODIUM CHLORIDE

View full screen / Print PDF » Download PDF ⇩
Transcript
Package leaflet: Information for the user



ENG

ACCUSOL 35 Potassium 2 mmol/l, Solution for haemofiltration,
haemodialysis and haemodiafiltration
Warnings and precautions

Read all of this leaflet carefully before you are given this medicine because it
contains important information for you:
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor.
• If you get any side effects talk to your doctor. This includes any
possible side effects not listed in this leaflet.

ACCUSOL 35 Potassium 2 mmol/l can only be used by or
under the direction of a doctor who has experience with
01852
haemofiltration, haemodialysis or haemodiafiltration techniques.
Your doctor will
• check the tubing containing ACCUSOL 35 regularly. The bag and tubing
will be immediately replaced if your doctor observes particles floating
in the fluid.
• measure the acidity, different salts and waste product levels in your
blood.
• ensure that their levels are correct and closely monitored during your
treatment.
• ensure that the fluid balance of your body is well maintained.
• check your blood glucose very carefully especially if you are diabetic.
• measure the potassium level in your blood regularly.
• ensure, just before use, the contents of the two chambers are mixed
by activating the long-seal (interchamber seal), followed by the
short SafetyMoon seal near the access port. If your doctor infuses
unmixed solution, your blood bicarbonate level may increase. This may
cause side effects such as nausea, drowsiness, headache, abnormal
heartbeat and difficulty of breathing.

What is in this leaflet
1. What ACCUSOL 35 Potassium 2 mmol/l is and what it is
used for
2. What you need to know before you are given
ACCUSOL 35 Potassium 2 mmol/l
3. How you will be given ACCUSOL 35 Potassium 2 mmol/l
4. Possible side effects
5 How to store ACCUSOL 35 Potassium 2 mmol/l
6. Contents of the pack and other information
1. What ACCUSOL 35 Potassium 2 mmol/l is and what it is
used for

Other medicines and ACCUSOL 35 Potassium 2 mmol/l

ACCUSOL 35 Potassium 2 mmol/l is a solution for haemofiltration,
haemodialysis and haemodiafiltration.

Tell your doctor if you are taking, have recently taken or might take any other
medicines.
Taking ACCUSOL 35 Potassium 2 mmol/l may affect and interact with other
medicines.
• If you are diabetic your glucose level will be carefully measured.
Your insulin dose will be adjusted as needed as this solution contains
glucose.
• If you take Vitamin D or medicines containing calcium, your blood
calcium level may be modified.
• If you take additional sodium bicarbonate, there is an increased risk of
abnormal salt and alkali levels (alkalosis) in your blood.
• If you use medicines for the heart known as cardiac glycosides you
may need potassium supplements. Your doctor will monitor you
closely during treatment.

ACCUSOL 35 Potassium 2 mmol/l is prescribed to you if you have temporary or
permanent kidney failure.
It purifies your blood of waste products; it corrects the acidity or alkalinity and
the level of salts in your blood. As a replacement fluid in haemodiafiltration and
haemofiltration, it can also be used as a source of salts and water for hydration.
ACCUSOL 35 solutions are supplied in a non-PVC bag with two chambers. The
two chambers are separated by a long-seal (interchamber seal). Prior to use,
the two chambers of ACCUSOL 35 solutions must first be mixed by activating
the long-seal (interchamber seal), followed by the activation of the short
SafetyMoon seal near the access port.
ACCUSOL 35 solutions must only be used by or under the direction of a doctor.

Pregnancy and breast-feeding
Tell your doctor if you are pregnant or breast-feeding. He will determine the
benefits versus the risks of using ACCUSOL 35 Potassium 2 mmol/l.

2. What you need to know before you are given
ACCUSOL 35 Potassium 2 mmol/l
Before starting the therapy, your doctor will ensure that you have a good access
to your vein and artery. He will also ensure that you do not present a high risk
of bleeding.
ACCUSOL 35 solutions are available in different potassium and glucose
concentrations. Your blood levels of potassium and glucose will be monitored
very closely to ensure that the most appropriate ACCUSOL 35 formulation is
used.

3. How you will be given ACCUSOL 35 Potassium 2 mmol/l
Depending on your therapy, your doctor will administer ACCUSOL 35
Potassium 2 mmol/l by way of the tubing from the dialysis machine.
The treatment by haemofiltration, haemodialysis or haemodiafiltration that
you receive will depend upon your clinical diagnosis, physical examination,
laboratory results and response to treatment.
Your doctor will determine the right formulation and amount of ACCUSOL 35
solutions for your clinical condition.

Your doctor will not give you ACCUSOL 35 Potassium
2 mmol/l:







if you do not have good access to the veins and/or arteries.
if you have an excessive risk of bleeding.
if you have a high level of bicarbonate in your blood.
if you have a potassium blood level too low, unless you are
simultaneously receiving potassium supplementation.
if you have a clinical condition whereby the current acidity or alkalinity
of your blood may worsen.
if you have kidney failure where waste products cannot be removed
from the blood stream by haemofiltration.

How much and how often?
Your doctor will decide and adjust the flow rate and volume of the solution to be
administered.
The amount of fluid required depends upon how ACCUSOL 35 Potassium
2 mmol/l is being used.

CB-30-01-852

1

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
2nd DRAFT (Mock-up)
RA TO APPROVE LAYOUT
AND FORMAT
Country

DATE 28 Feb 2013
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

RA Proofreading Checklist
Product Information proofread as
per RA SOP CE-RAPV-009

Product name,strength,composition
(API & excipients)

Compliance with National
Regulations

Consistency check with all figures
cited in the product information

Barcodes, Symbols and Reimbursement Information

Storage Conditions and Shelf-Life

If you are adult or elderly and
• treated for chronic renal failure with ACCUSOL 35 Potassium 2 mmol/l
as substitution solution, you should receive 7 to 35 ml/kg/hr or more.
• treated for temporary kidney failure with ACCUSOL 35 Potassium
2 mmol/l as substitution solution, you should receive 20 to 35 ml/kg/hr
or more.
• treated for chronic or temporary kidney failure with ACCUSOL 35
Potassium 2 mmol/l as dialysis solution, the amount of solution will be
determined by frequency and duration of treatment.

The 5000 ml of final solution results from the mixing of 3750 ml of solution ‘A’
with 1250 ml of solution ‘B’.

Ionic Composition of Final Solution:
Per 1000 ml ACCUSOL 35
1.75 mmol
0.5 mmol
140 mmol
2 mmol
111.3 mmol

Calcium (Ca++)
Magnesium (Mg++)
Sodium (Na+)
Potassium (K+)
Chloride (Cl-)
Glucose Anhydrous

4. Possible side effects

5.55 mmol

Bicarbonate (HCO3-)

35 mmol
296 mOsm/l

Theoretical Osmolarity:

Like all medicines this medicine can cause side effects, but not everyone gets
them.
Possible rare side-effects (occurring in less than 1 in 1000 patients) of
ACCUSOL 35 Potassium 2 mmol/l may include
• Low blood glucose (hypoglycaemia).
You may experience other possible side effects. They may not all be due to the
solutions or treatment. The potential undesirable effects that may occur are:
• Reduction (hypovolaemia) or increase (hypervolaemia) in body fluid
volume
• Reduction (hypotension) or increase (hypertension) in blood pressure
• Very low blood phosphate (hypophosphataemia)
• Disturbance in the alkali level in your blood (alkalosis)
• Feeling sick
• Vomiting
• Muscle cramps
• Bleeding disorder
• Infection
• Shortness of breath, irregular breathing (caused by air bubbles getting
into the blood stream)
• Disturbance in different salt levels in your blood (e.g. disturbance in
sodium, potassium, calcium in your blood)
• Increase blood clotting.
If you get any side effects, talk to your doctor. This includes any side effects not
listed in the leaflet.

The other ingredients are: Water for Injections, Hydrochloric acid, Sodium
hydroxide and Disodium phosphate dihydrate.

What ACCUSOL 35 Potassium 2 mmol/l looks like and
contents of the pack
ACCUSOL 35 Potassium 2 mmol/l is supplied in a carton box containing two
units of 5 litre two-chamber non-PVC bags.
Each bag is over-wrapped in its overpouch.
The solution in the bag is clear and colourless.

Marketing Authorisation Holder:
Baxter Healthcare Ltd.,
Caxton Way,
Thetford, Norfolk,
IP24 3SE, United Kingdom
Phone: + 44 (0) 1635 206345

Manufacturers:
Baxter Healthcare S.A.
Moneen Road
Castlebar
County Mayo – Ireland

Bieffe Medital S.p.A.
Via Nuova Provinciale
23034 Grosotto
Italy

This leaflet was last approved in:

Baxter, Accusol and Clear-Flex are trademarks of Baxter International Inc.

5. How to store ACCUSOL 35 Potassium 2 mmol/l
Keep this medicine out of the sight and reach of children.
Store between 4°C and 25°C. Do not use this medicine after the expiry date
which is stated on the label and carton after ‘Exp.’ ‘The expiry date refers to the
last day of that month.
Your doctor will not use ACCUSOL 35 if the solution is not clear or if the
container is damaged.

6. Contents of the pack and other information
Name of the Medicinal Product
ACCUSOL 35 Potassium 2 mmol/l, Solutions for haemofiltration, haemodialysis
and haemodiafiltration.

The composition of the solution ACCUSOL 35 Potassium
2 mmol/l is:
Ingredients
Large chamber ‘A’
Calcium chloride dihydrate
Magnesium chloride hexahydrate
Sodium chloride
Potassium chloride
Glucose monohydrate
Small chamber ‘B’
Sodium bicarbonate

Per 1000 ml ACCUSOL 35
Potassium 2 mmol/l
0.343 g
0.136 g
7.52 g
0.199 g
1.47 g
13.4 g
CB-30-01-852

2

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
2nd DRAFT (Mock-up)
RA TO APPROVE LAYOUT
AND FORMAT
Country

DATE 28 Feb 2013
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

RA Proofreading Checklist
Product Information proofread as
per RA SOP CE-RAPV-009

Product name,strength,composition
(API & excipients)

Compliance with National
Regulations

Consistency check with all figures
cited in the product information

Barcodes, Symbols and Reimbursement Information

Storage Conditions and Shelf-Life

The following information is intended for medical or Healthcare professionals only



INFORMATION FOR THE HEALTH PROFESSIONAL 

ENG

ACCUSOL 35 Potassium 2 mmol/l, Solution for haemofiltration, haemodialysis
and haemodiafiltration
1. NAME OF THE MEDICINAL PRODUCT

Elderly: as for adults
These fluid volume recommendations may be adjusted by the prescribing
physician according to the patient’s clinical status.
ACCUSOL 35 can be administered into the extracorporeal blood circuit either in
pre- and/or post- dilution mode according to the physician’s prescription.

ACCUSOL 35 Potassium 2 mmol/l
Solution for haemofiltration, haemodialysis and haemodiafiltration
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Composition
Large chamber ‘A’
Calcium chloride dihydrate
Magnesium chloride hexahydrate
Sodium chloride
Potassium chloride
Glucose monohydrate
Small chamber ‘B’
Sodium bicarbonate

Per 1000 ml ACCUSOL 35

Final solution after mixing
Calcium chloride dihydrate
Magnesium chloride hexahydrate
Sodium chloride
Potassium chloride
Glucose anhydrous
Sodium bicarbonate

Per 1000 ml ACCUSOL 35

0.257 g

0.102 g

6.12 g

0.149 g

1.0 g

2.94 g







0.343 g
0.136 g
7.52 g
0.199 g
1.47 g



13.4 g

ACCUSOL 35 as dialysis solution
The prescription and amount of dialysis solution depend upon the mode of
therapy, frequency and duration of treatment and will be selected by the
prescribing physician according to the patient’s clinical status.
Administration:
Haemodialysis: via the dialysis compartment of the dialyser.
Haemofiltration: via the arterial or venous blood line.
After removal of the overpouch, immediately open the long-seal (interchamber
seal) to mix the two solutions and then open the short SafetyMoon seal (seal
near access port) to allow administration of the mixed solution. For instructions
for use and handling, please refer to section 5.5.
4.3 Contraindications
Solution dependent contraindications
• Hypokalaemia, if no simultaneous adapted potassium
supplementation.
• Metabolic alkalosis.
Haemofiltration / haemodialysis / haemodiafiltration dependent contraindication
due to the technical procedure itself:
• Renal failure with increased hypercatabolism in cases where uraemic
symptoms can no longer be relieved by haemofiltration.
• Inadequate blood flow from vascular access.
• If there is a high risk of haemorrhage on account of systemic
anticoagulation

Equivalent to the following ionic composition:
Ionic Composition of Final Solution
Calcium (Ca++)
Magnesium (Mg++)
Sodium (Na+)
Potassium (K+)
Chloride (Cl-)
Glucose Anhydrous
Bicarbonate (HCO3-)
Theoretical Osmolarity:

Per 1000 ml ACCUSOL 35

1.75 mmol

0.5 mmol

140 mmol

2 mmol

111.3 mmol

5.55 mmol

35 mmol

296 mOsm/l

The 5000 ml of final solution results from mixing 3750 ml of solution ‘A’ with
1250 ml of solution ‘B’.
The pH of the final solution is between 7.0 – 7.5
The number “35” in the name specifies the buffer concentration of the solution
(bicarbonate = 35 mmol/l).
3. PHARMACEUTICAL FORM
Solution for haemofiltration, haemodialysis and haemodiafiltration.
ACCUSOL 35 is a sterile, non pyrogenic, clear and colourless solution.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
ACCUSOL 35 is indicated for the treatment of acute and chronic renal failure, as
substitution solution in haemofiltration and haemodiafiltration, and as dialysis
solution in haemodialysis and haemodiafiltration.
4.2 Posology and method of administration
For haemofiltration, haemodialysis and haemodiafiltration.
ACCUSOL 35 as substitution solution
The amount of substitution solution to be administered in adults is determined
by the ultrafiltration rate and is set for each individual case to ensure an
adequate electrolyte fluid balance.
Adults:
• Chronic renal failure: 7 to 35 ml/kg/hr,
• Acute renal failure: 20 to 35 ml/kg/hr,
3

4.4 Special warnings and precautions for use
• ACCUSOL 35 solution must only be used by or under the direction
of a physician experienced in haemofiltration, haemodialysis or
haemodiafiltration techniques,
• White particulate formation of calcium carbonate has been observed
in the pre-dilution and post-dilution CRRT lines in association with
the use of ACCUSOL 35. Therefore every 30 minutes during CRRT with
ACCUSOL 35, pre- and post-dilution lines should be closely inspected
to verify that the solution in the tubing is clear and without particles. In
some cases precipitation may not appear until several hours after the
start of therapy.

If precipitate is observed, the ACCUSOL 35 solution and CRRT
tubing lines must be replaced immediately and the patient carefully
monitored,
• Fluid balance must be carefully monitored,
• Acid-base balance must be carefully monitored,
• Similarly, electrolyte balance (chloraemia, phosphataemia, calcaemia,
magnesaemia and natraemia) should be monitored regularly to detect
any potential imbalance,
• Kalaemia must be monitored regularly before and during treatment.
If hypokalaemia is present or starts to develop, supplementation of
potassium may be required. If hyperkalaemia starts to develop, an
increase in the filtration rate and/or changing to a substitution solution
with a lower potassium concentration may be indicated as well as
usual measures of intensive care medicine,
• Blood glucose levels must be monitored closely, especially in diabetic
patients,
• In case the long-seal (interchamber seal) is not opened (i.e. only
short SafetyMoon seal near access port opens) and the solution of
the small chamber “B” is given, alkalosis may arise. Most common
clinical signs / symptoms of alkalosis are nausea, lethargy, headache,
arrhythmia, respiratory depression.
CB-30-01-852

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
2nd DRAFT (Mock-up)
RA TO APPROVE LAYOUT
AND FORMAT
Country

DATE 28 Feb 2013
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

RA Proofreading Checklist
Product Information proofread as
per RA SOP CE-RAPV-009

Product name,strength,composition
(API & excipients)

Compliance with National
Regulations

Consistency check with all figures
cited in the product information

Barcodes, Symbols and Reimbursement Information

Storage Conditions and Shelf-Life

4.5 Interaction with other medicinal products and other forms of interaction
When prescribing ACCUSOL 35 Potassium 2 mmol/l, consideration should be
given to the potential interactions between this treatment and other concomitant
therapies related to other pre-existing conditions.
• Blood concentration of other medicinal products may be altered during
haemodialysis, haemofiltration and haemodiafiltration.
• Plasma levels of potassium in patients using cardiac glycosides must
be carefully monitored due to an increased risk of hypokalaemia
associated arrhythmias.
• Vitamin D and medicinal products containing calcium can increase the
risk of hypercalcaemia (eg calcium carbonate acting as a chelator of
potassium).
• The additional substitution of sodium bicarbonate can increase the risk
of metabolic alkalosis.

5. PHARMACEUTICAL PARTICULARS
5.1 Incompatibilities
This medicinal product must not be mixed with other medicinal products except
those mentioned in section 5.5
5.2 Shelf life
Shelf life
12 months when stored in the overpouch.
Shelf life after mixing
ACCUSOL 35, once removed from the overpouch and mixed should be used
within 24 hours.
5.3 Special precautions for storage
Store between 4°C and 25°C.

4.6 Fertility, pregnancy and lactation
There are no preclinical or clinical data on the use of ACCUSOL 35 during
pregnancy and lactation. ACCUSOL 35 should only be administered to pregnant
and lactating women if clearly needed.

5.4 Nature and contents of container
ACCUSOL 35 is stored in a non-PVC two-chamber bag made of a coextruded
film of Polypropylene, Polyamide and a blend of Polypropylene, SEBS and
Polyethylene (CLEAR-FLEX). A long-seal (interchamber seal) separates the two
chambers.
The large chamber ‘A’ is fitted with a medication port and the small chamber ‘B’
is fitted with an access port for connection to a suitable administration set.
The two-chamber bag is presented in a protective transparent overpouch made
of copolymers.
The volume of the container after mixing is 5000 ml (3750 ml in the large
chamber and 1250 ml in the small chamber).
ACCUSOL 35 is available as 2 x 5000 ml per box.

4.7 Effects on ability to drive and use machines
Not relevant.
4.8 Undesirable effects
The undesirable effects reported are based on adverse event reports from
clinical trials (see (1) below), which were assessed by the investigator to be
related to ACCUSOL, as well as from a literature review (see (2) below).
The frequency has been evaluated by using the following criteria:
very common (> 1/10), common (> 1/100, < 1/10), uncommon (> 1/1,000,
< 1/100), rare (> 1/10,000, < 1/1,000) and very rare (< 1/10,000).

5.5 Special precautions for disposal and other handling
• Check the integrity of the product. If one of the seals is opened
prematurely, do not use the bag. In case of damage, discard the
container.
• Do not administer unless the solution is clear.
• Aseptic technique should be observed throughout the whole procedure.
• Concomitant drugs may be added through the medication port in the
larger chamber. Drug compatibility must be checked before admixture.
Add the medication and activate the long-seal (interchamber seal)
immediately. The product must be used immediately after any drug
addition.
• After removal of the overpouch, immediately open the long-seal
(interchamber seal) to mix the two solutions. Ensure the long-seal
(interchamber seal) is completely activated and the two solutions are
completely mixed. Then open the short Safety Moon seal (seal near
access port) to allow administration of the mixed solution. Connect to
the patient line and activate the access port. The solution must be used
within 24 hours of mixing.
• Discard any unused remaining solution.
• For single use only.
• Use ACCUSOL 35 only with adequate equipment able to monitor the
therapy.

1) Clinical Trials
System Organ
Class
Metabolic and
Nutritional

Adverse Drug
Reaction
Hypoglycaemia
NOS

Frequency
Rare

Procedure
related
Yes

Solution
related
Yes

2) Literature review
The undesirable effects below listed reflect the type of undesirable effects that
may be reported with haemofiltration or haemodialysis solutions.
• Potential adverse reactions related to the treatment may include
nausea, vomiting, muscle cramps, hypotension, bleeding, clotting,
infection and air embolism.
• Potential adverse reactions related to the product may include
metabolic alkalosis, electrolyte disturbances and/or fluid imbalances:
hypophosphataemia, hypoglycaemia, hypo- and hypervolaemia, hypoand hypertension.
4.9 Overdose
Overdose should not occur if the fluid and electrolyte balances are monitored
regularly as recommended in section 4.4. Overdose may lead to hypervolaemia
and electrolyte disturbances. These symptoms can be corrected by adjusting the
ultrafiltration rate and the volume of solution administered.
Electrolyte imbalances should be managed according to the specific electrolyte
disturbance.

6. MARKETING AUTHORISATION HOLDER
Baxter Healthcare Ltd.,
Caxton Way,
Thetford, Norfolk,
IP24 3SE, United Kingdom
Phone: + 44 (0) 1635 206345
7. MARKETING AUTHORISATION NUMBER(S)

01852

PL0116/0415
PA 167/123/1

CB-30-01-852

4

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
2nd DRAFT (Mock-up)
RA TO APPROVE LAYOUT
AND FORMAT
Country

DATE 28 Feb 2013
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

RA Proofreading Checklist
Product Information proofread as
per RA SOP CE-RAPV-009

Product name,strength,composition
(API & excipients)

Compliance with National
Regulations

Consistency check with all figures
cited in the product information

Barcodes, Symbols and Reimbursement Information

Storage Conditions and Shelf-Life

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide